MIMESIS program for Influenza, HRV, RSV, TB, Zika and triple negative breast cancer
To scale-up its drug-discovery approach, the European Commission has granted ENYO Pharma with an Horizon 2020 Research and Innovation program for its MIMESIS project. For MIMESIS project, a library of 10,000 small molecules has been designed, based on biomimetism, and screened in functional assays. Six disease contexts related to Oncology, Respiratory viral infections (RSV, influenza, HRV) and Neglected pathogens (Zika virus, tuberculosis) correspond to those functional assays. Within 2 years, the goal is to design new therapeutic starting points and preclinical assets that modulate novel human targets, ready for further development with future partners.